LTZ Therapeutics

LTZ Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company has pioneered a proprietary Universal Myeloid Cell Engager (U-MCE) platform that leverages reverse translational science to activate myeloid cells, such as macrophages. This mechanism aims to enhance phagocytosis, reprogram the immunosuppressive tumor microenvironment, and stimulate a durable anti-tumor immune response. Their lead clinical asset, LTZ-301, is a bi-specific antibody designed to redirect monocytes and macrophages to target cells, currently being evaluated in clinical studies for B-cell lymphoma and autoimmune conditions.

This technology addresses significant unmet clinical needs by targeting mechanisms that have historically been resistant to traditional therapies. By focusing on myeloid biology, LTZ Therapeutics seeks to improve clinical outcomes and safety profiles for patients. The company maintains a global presence with operations in Redwood City, California, and Shenzhen, China. They have established strategic research and development collaborations with major pharmaceutical companies, including Eli Lilly and GSK, to advance their pipeline. As of mid-2026, the company has secured substantial venture financing to support its ongoing clinical trials and research initiatives.